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Abstract—Silicon membranes with highly uniform nanopore
sizes fabricated using microelectromechanical systems
(MEMS) technology allow for the development of miniatur-
ized implants such as those needed for renal replacement
therapies. However, the blood compatibility of silicon has
thus far been an unresolved issue in the use of these
substrates in implantable biomedical devices. We report the
results of hemocompatibility studies using bare silicon,
polysilicon, and modified silicon substrates. The surface
modifications tested have been shown to reduce protein and/
or platelet adhesion, thus potentially improving biocompat-
ibility of silicon. Hemocompatibility was evaluated under
four categories—coagulation (thrombin–antithrombin com-
plex, TAT generation), complement activation (complement
protein, C3a production), platelet activation (P-selectin,
CD62P expression), and platelet adhesion. Our tests revealed
that all silicon substrates display low coagulation and
complement activation, comparable to that of Teflon and
stainless steel, two materials commonly used in medical
implants, and significantly lower than that of diethylamino-
ethyl (DEAE) cellulose, a polymer used in dialysis mem-
branes. Unmodified silicon and polysilicon showed
significant platelet attachment; however, the surface modifi-
cations on silicon reduced platelet adhesion and activation to
levels comparable to that on Teflon. These results suggest
that surface-modified silicon substrates are viable for the
development of miniaturized renal replacement systems.
Keywords—Surface modification, Coagulation, Complement,
Platelet adhesion, Activation.
INTRODUCTION
Silicon-based materials are being used in the fabri-
cation of a wide range of biomedical devices for
diagnostic and therapeutic applications. These include
devices for drug delivery,3 neural electrodes,27 and
implantable sensors,5 many of which are being con-
sidered for use within the body. One such promising
technology is the development of miniaturized renal
replacement devices using silicon nanoporous mem-
branes.8 Such devices allow for extended dialysis each
day leading to better outcomes and improved quality
of life for patients with kidney failure. Current tech-
nologies make use of polydisperse polymer membranes
which are limited by the need for high driving pressures
for circulation and clearance. In contrast, silicon
membranes with highly uniform pore sizes fabricated
using microelectromechanical systems (MEMS) tech-
nology offer a promising approach for the production
of miniaturized, high-performance renal replacement
systems.19 Moreover, these membranes have been
shown to support the growth and function of human
renal proximal tubule cells indicating that they do not
exhibit cytotoxicity.8
However, it is important that the single crystal sili-
con substrates display minimal adverse reactions in
terms of blood compatibility (low surface coagulation,
complement and/or platelet activation, and platelet
adhesion) for effective use as the membrane material.
Blood material interactions are especially important
for hemodialysis due to the chronic exposure of blood
to the membrane surface during treatment.4 Here
we evaluate the blood compatibility of solid silicon
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substrates with and without surface modification by
polymer conjugation. We have examined four types of
surface modifications in this study, all of which have
been shown to improve biocompatibility by preventing
protein and/or platelet adhesion on the underlying
surface. The first two are polyethylene glycol (PEG)
conjugated to the surface using liquid23 and vapor-
based deposition techniques, respectively. PEG has
been shown to reduce non-specific protein adsorption
and fouling on silicon surfaces.7 Solvent-free vapor
deposition of PEG has been demonstrated to reduce
protein adsorption by up to 80% on silicon-based
surfaces.25 Furthermore, PEG films have shown long-
term resistance to biofouling by reducing protein
adsorption on silicon surfaces for up to four weeks
under aqueous in vivo-like conditions.29
The third polymer is a glycocalyx-mimetic dextran-
modified polyvinylamine (PVAm) surfactant which has
been shown to reduce platelet adhesion.10 A zwitter-
ionic polymer, polysulfobetaine methacrylate
(pSBMA), shown to have good antifouling properties,
was the fourth surface modification tested in the
study.2 Additionally, polysilicon substrates used in
MEMS fabrication to create uniformly porous mem-
branes7 were also included in this study.
Previous studies that have examined blood com-
patibility of silicon primarily focused on platelet
adhesion tests of silicon-based substrates under static
conditions.33,35 Here we extend these studies to inves-
tigate various aspects of hemocompatibility such as
coagulation and complement activation, in addition to
platelet activation. Accordingly, the surfaces were
incubated with freshly drawn anticoagulated human
whole blood or platelet-rich plasma (PRP) and tested
for four different markers reflecting the following test
categories—coagulation (thrombin–antithrombin
complex, TAT generation), complement activation
(formation of activated complement protein C3a),
platelet activation (expression of P-selectin, CD62P),
and platelet adhesion.
Hemocompatibility of the silicon-based substrates
was compared to Teflon (polytetrafluoroethylene,
PTFE) and medical grade stainless steel, two sub-
strates that are routinely used in various medical
implants.15,16 Both these surfaces display excellent
blood compatibility32,34 and serve as negative controls
in this study. Diethylaminoethyl (DEAE) cellulose, a
polymer used in commercially available dialysis mem-
branes4 was also tested to compare the performance of
the silicon-based substrates with a conventional dia-
lyzer material. Previously it has been shown that
DEAE cellulose has advantages in terms of low platelet
and complement activation, but exhibits high levels of
TAT generation.4,28 Thus, it is not the ideal choice of
dialyzer material with respect to surface coagulation.
Other polymer membranes such as polysulfone have
more favorable coagulation properties in comparison
to DEAE cellulose.4 However, this material was se-
lected as the reference substrate because it could also
serve as a positive control in our experiments. Aden-
osine diphosphate (ADP) is a known agonist of
platelet activation.22 Upon activation, ADP is released
from the dense granules of platelets, and aids in
platelet aggregation and further activation. Hence,
ADP was used as a positive control for platelet acti-
vation studies.
MATERIALS AND METHODS
Materials
All chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA) unless specified. Poly(N-vinyl
dextran aldonamide-co-N-vinyl hexanoamide) (PVAm-
Dex/Hex) was purchased from Greatbatch, Inc.
(Clarence, NY, USA) and 2-bromo-2-methyl-N-3-
[(trimethoxysilyl)propyl]-propanamide (BrTMOS) was
synthesized according to literature.17 Virgin, prime-
grade, single side polished, 500 lm thick, Æ100æ-ori-
ented, n-type, silicon wafers were used in the study.
Deposition of polysilicon was performed at Cleveland
Clinic. DEAE cellulose (Whatman, Piscataway, NJ,
USA), Teflon (Scientific Commodities, Lake Havasu
City, AZ, USA) and stainless steel (Feather Safety
Razor, Medical Division, Kita-ku, Osaka, Japan) were
used as reference materials.
Substrate Preparation
Liquid-based deposition of PEG on silicon was
performed as described in previously published
reports.23 Briefly, the single crystal silicon substrates
were first sonicated in 70% ethanol for 10 min and
then dried with nitrogen. Substrates were then oxidized
in a 20:80 hydrogen peroxide (30%) and sulfuric acid
(96%) mixture for 10 min at 120 C. Substrates were
then washed and sonicated for 10 min in deionized
water and dried with nitrogen. Immediately, silicon
substrates were immersed in a solution of 3 mM
2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane
in toluene for 18 h at room temperature. Finally, the
substrates were extensively washed with toluene, eth-
anol, and deionized water, before being dried with
nitrogen to prepare the PEG-conjugated substrates.
Vapor-based deposition of PEG on silicon was
performed at UCSF according to protocols developed
in our laboratory. Single crystal silicon substrates were
cleaned with a 3:1 sulfuric acid:hydrogen peroxide
solution, rinsed in deionized water, and dried with
Hemocompatibility of Silicon Substrates for Implants 1297
nitrogen. Silicon pieces were then treated with oxygen
plasma (200 W, 0.5 mTorr) for 5 min prior to being
placed in the Teflon deposition chamber. The deposi-
tion chamber was purged with nitrogen, and a hot
plate was used to maintain silicon surface tempera-
ture of 120 C. [2-Methoxy(polyethyleneoxy)propyl]
trimethoxysilane (PEG-silane) was vaporized at 250 C
in a closed stainless steel loop and subsequently
released into the deposition chamber. Four vapor
exposures for 30 min each were performed before sil-
icon samples were removed for use.
PVAm-modified silicon substrates were prepared at
Cleveland Clinic according to protocols published in
our laboratory.18 Briefly, single crystal silicon wafers
were plasma cleaned and placed in a solution of
octadecyltrichlorosilane for 30 min. The wafers were
then washed twice with dried chloroform before
immersion into an aqueous solution of PVAm-Dex/
Hex for 24 h. The substrates were finally rinsed with
deionized water and air dried to prepare the PVAm-
modified silicon substrates.
The pSBMA-modified substrates were also fabri-
cated at Cleveland Clinic using protocols published by
our laboratory.17 Cleanedwafers of single crystal silicon
were placed in an anhydrous bicyclohexyl solution of
BrTMOS for 2 h, rinsed, air dried and then placed in a
flask under nitrogen. Polymerization was carried out
using a solution of [2-(methacryloyloxy)ethyl]dimethyl-
(3-sulfopropyl)ammonium hydroxidemonomer (SBMA)
and 2,2¢-bipyridyl (BPY) dissolved in a degassed solu-
tion of methanol and deionized water, to which cop-
per(II) bromide and copper(I) bromide had been added.
The substrates were then rinsed with ethanol and water
and stored in deionized water overnight and then air
dried for use in the study.
The surface of a silicon wafer oxidizes to form sili-
con dioxide when exposed to air. Our unmodified
silicon surfaces are hence Si/SiO2 surfaces. The
unmodified silicon substrates were cleaned with pira-
nha (3:1 H2SO4/H2O2 mixture) and dried with nitrogen
before use. All substrates (except DEAE cellulose)
were rinsed with 70% ethanol and dried before use.
The substrates were all sterilized using UV radiation
for 5 min prior to blood or plasma incubation.
Blood Collection
Blood was drawn at the UCSF Blood Center from
healthy human donors using 3.8% citrate (Fisher Sci-
entific, Pittsburgh, PA, USA) or 17 IU/mL heparin
(Fisher Scientific, Pittsburgh, PA, USA) as anticoagu-
lant. Informed consent was obtained from donors prior
to blood donation. Heparin is a commonly used anti-
coagulant in blood compatibility testing of biomaterials
in vitro9,31 and was selected as the anticoagulant for
TAT generation studies. Unfractionated heparin
(UFH) binds antithrombin and converts it into a more
efficient inhibitor of thrombin and other coagulation
factors such as factor Xa, factor IXa, and factor XIIa.11
At high concentrations, heparin binds heparin cofactor
II to inhibit thrombin independent of antithrombin;
however, it also binds to platelets and induces their
aggregation. Heparin also binds anaphylotoxins such
as the complement protein C3a.30 Sodium citrate neu-
tralizes coagulation factor activation. Since citrate is a
calcium chelator, it reduces the ionized calcium con-
centration in plasma leading to enhanced GPIIb/IIIa
binding and inhibition of platelet aggregation.24 Thus,
citrate does not cause spontaneous platelet activation
in vitro and any activation that is seen is due to the
surface of the biomaterial itself. For these reasons,
citrate was selected for the platelet and complement
activation studies.
Blood samples were stored on ice until the start of
experiments based on previously published reports in
literature,1,20 and in accordance with the guidelines of
the International Standard ISO 10993 Part 4—Selec-
tion of tests for interactions with blood.13 All blood
samples were handled in a similar manner and stored
on ice for an equivalent amount of time (60 ± 5 min).
Whole blood was centrifuged at 1000 rpm for 10 min
at room temperature to obtain PRP for platelet
adhesion studies. Platelet counts were obtained using a
Hemavet950 (Drew Scientific, Oxford, CT, USA).
Blood Incubation and Analysis
Flow is the natural state of blood and flow studies
are the ideal representation of conditions in vivo. Our
experiments conducted under non-perfusion condi-
tions are preliminary studies indicative of data
obtained with flow-based studies. In flow-based sys-
tems, blood is exposed to additional foreign material
such as tubing, and shear stress due to pumping, all of
which have been shown to increase the activation of
blood components.32 Streller et al. have shown that
data obtained under non-flow conditions are repre-
sentative of flow-based studies using control substrates
such as Teflon, glass, and polyethersulfone. Consider-
ing these aspects, we decided to conduct preliminary
studies under static conditions to examine the relative
difference in activation levels between bare silicon and
surface-modified silicon substrates. The substrates
were, however, incubated on a gentle shaker (50 shakes
per min) to avoid sedimentation of platelets.9,31
400 lL of whole blood from three donors was dis-
pensed onto the substrates (10 mm 9 10 mm) placed
in 24-well tissue culture polystyrene (TCPS) micro-
plates. Four replicates were used for each donor for
all substrates except polysilicon, where only three
MUTHUSUBRAMANIAM et al.1298
replicates were available for one of the donors due
to inadvertent error in sample handling. For the C3a
studies, substrates were mounted on Teflon spacers
placed on tissue culture dishes to minimize possible
activation from TCPS (Supplementary Figure S1). The
substrates were incubated for 2 h at 37 C on a gentle
shaker. Commercial ELISAs were used to characterize
TAT generation (Enzygnost TAT micro, Siemens
Healthcare Diagnostics, Deerfield, IL, USA) and C3a
formation (Human C3a ELISA Kit, BD Biosciences,
San Jose, CA, USA). Blood samples were mixed with
specific inhibitors and centrifuged to collect plasma
according to the manufacturer’s protocols. Plasma
samples were frozen at 270 C until further analysis.
Surface Analysis after Incubation
Platelet adhesion and activation was visualized using
immunofluorescence staining for the platelet marker,
CD41 (Abcam, Cambridge, MA, USA) and activated
platelet marker, CD62P (Abcam, Cambridge, MA,
USA). 200 lL of PRP (3.3 9 105 platelets/lL) from
one donor was dispensed onto the substrates
(10 mm 9 10 mm) mounted on Teflon spacers and
incubated for 2 h at 37 C on a gentle shaker. Three
replicates were used for all substrates except polysilicon,
where only two replicates were available due to inad-
vertent error in sample handling. The platelets were
treated with ADP in solution. ADP (40 lM final con-
centration in PRP) was added to PRP and dispensed on
single crystal silicon (10 mm 9 10 mm) in triplicate for
use as the positive control. After 2 h, PRP was removed
and the substrates were transferred to a 24-well plate
and washed with phosphate-buffered saline (PBS). The
platelets were fixed in 4% paraformaldehyde (Fisher
Scientific, Pittsburgh, PA, USA) for 15 min, and
blocked in 1% bovine serum albumin for 30 min.
Platelets were double labeled as follows: substrates were
first incubated with antihuman CD62P mouse mono-
clonal antibody, diluted 1:50 in PBS for 60 min followed
by Alexa Fluor 546 donkey anti-mouse antibody
(Invitrogen, Carlsbad, CA, USA) diluted 1:100 in PBS
for 60 min. Finally the samples were incubated with
antihuman CD41 FITC-labeled mouse monoclonal
antibody diluted 1:300 in PBS for 60 min. Four images
were acquired per replicate using a NikonEclipse Ti-E
motorized inverted microscope to obtain a total of 12
images per substrate. Data analysis was performed
using Fiji, an Open Source image analysis package
based on ImageJ (http://pacific.mpi-cbg.de/).
Statistical Analysis
Statistically significant differences were estimated
using analysis of variance (ANOVA) tests. For group
differences shown to be significant by ANOVA,
sequential Holm t-tests were performed to detect dif-
ferences between specific pairs of substrates.
RESULTS AND DISCUSSION
Surface Coagulation
Activated thrombin is inhibited by antithrombin-III
to form a proteinase/inhibitor complex (TAT), the
concentration of which is used as ameasure of thrombin
activation and coagulation.32 Generation of TAT
complex after whole blood incubation with the sub-
strates was therefore determined to evaluate surface
coagulation. As seen from Fig. 1, the most striking
difference is that TAT generation is drastically reduced
(~25- to 50-fold, p< 0.001) on the silicon-based sub-
strates when compared to DEAE cellulose. This indi-
cates that the silicon-based substrates display superior
anticoagulation properties when compared to the highly
thrombogenicDEAE cellulose surface. Previously it has
been shown that DEAE cellulose exhibits high levels of
TAT generation.4,28 This is in good agreement with our
data where DEAE cellulose acts as a positive control
exhibiting high levels of TAT formation.
Most importantly, there is no significant difference
in TAT generation with the single crystal silicon,
modified silicon and polysilicon substrates when com-
pared to Teflon and stainless steel. Thus, the silicon-
based substrates display excellent anticoagulation,
comparable to the negative control substrates.
Complement Activation
C3a anaphylatoxin is produced upon activation of
the classical or alternate complement pathways. The
amount of C3a formed after whole blood incubation
with the substrates is therefore used as a measure of
complement activation.12 As seen from Fig. 2, C3a
formation on the silicon-based substrates is substan-
tially reduced (~3- to 4-fold, p< 0.001) in comparison
to DEAE cellulose. Previous studies have shown that
modification of cellulose by the incorporation of
DEAE groups offers certain advantages such as
reduced complement activation.4,28 However, the sili-
con substrates exhibit even lower levels of C3a forma-
tion, indicating that they compare even more favorably
thanDEAEcellulose in termsof complement activation.
More importantly, there is no significant difference
in C3a formation between the single crystal silicon,
polysilicon and modified silicon substrates with respect
to Teflon and stainless steel indicating that these
substrates do not exhibit significant complement
activation.
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Platelet Adhesion and Activation
CD41 is an integrin heterodimer consisting of a
heavy chain (GPIIb alpha) and a light chain (GPIIb
beta) that is expressed on the surface of platelets. The
alpha IIb chain forms a platelet glycoprotein complex
with another molecule, CD61, and thus aids in platelet
adhesion and aggregation. The CD62P antigen is a
member of the selectin family of cellular adhesion
molecules located in the storage granules of platelets.
Upon activation, CD62P is released and stably
expressed on the surface of activated platelets. Thus,
CD41 and CD62P can be used as markers for platelet
adhesion and activation, respectively.6 The fibrous
texture of DEAE cellulose made it difficult to visualize
platelet staining on this surface. Hence ADP, a known
platelet activator, was used as the positive control for
this study. Previous studies have established Teflon as
a material that displays minimal platelet activation
and thrombosis.32 Hence Teflon was selected as the as
the negative control for further studies with platelet
activation.
In this work, blood samples were stored on ice
based on protocols from previously published reports
in literature.1,20 Blood storage on ice is also in accor-
dance with the guidelines of the International Standard
ISO 10993 Part 4—Selection of tests for interactions
FIGURE 1. Surface coagulation presented as a measure of TAT generation after whole blood incubation with the substrates. Data
is presented as average 6 standard deviation. *p< 0.001 vs. Teflon.
FIGURE 2. Complement activation presented as amount of C3a formed after whole blood incubation with the substrates. Data is
presented as average 6 standard deviation. *p< 0.001 vs. Teflon.
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with blood.13 Bergseth et al., report that the ideal
conditions for storing blood samples collected for
platelet activation studies is to place them on ice for
30 min.1 Another study that specifically looked at
optimizing blood storage conditions reported that the
percentage of CD62P positive platelets does not
change in anticoagulated blood samples stored at 4 C
over a period of 180 min,20 indicating that chilling
does not change P-selectin levels at least over the time
period relevant to our studies. In contrast, room tem-
perature storage leads to the secretion of metabolic
products such as lactate resulting in low pH and
decreased platelet viability.14,26 At room temperature,
platelets get activated as indicated by the secretion of
beta-thromboglobulin, platelet factor-4, and P-selectin,
all of which are known markers for platelet activation.
For these aforementioned reasons, the choice was
made to store the blood samples on ice until the start
of experiments. Additionally, we observed minimal to
no platelet activation on the surface-modified silicon
substrates and Teflon control (Figs. 4d–4h). Thus, it is
unlikely that platelet activation is caused by storage of
blood samples on ice.
As seen in Fig. 3, single crystal silicon and polysil-
icon display extensive platelet adhesion and activation
as shown by labeling for CD41 (green), CD62P (red)
and colocalization (Figs. 4a, 4b). However, platelet
spreading on these two substrates is still considerably
lesser compared to the ADP/silicon substrate (Fig. 4c).
Also, the ratio of activated platelets on ADP/silicon
(0.92) is higher than that on either bare silicon (0.8) or
polysilicon (0.5), respectively (Fig. 5). Increase in
platelet spreading has been correlated with higher
levels of platelet activation.33 Thus, the dramatic
increase in platelet size (~10-fold as seen in Fig. 5,
p< 0.001) on ADP/silicon compared to bare silicon or
polysilicon establishes ADP as a good positive control
for this study. Platelet spreading on the ADP/silicon
surface also contributes to the lower platelet count per
unit area as seen in Fig. 5.
Notably, the polymer-conjugated silicon substrates
show minimal to no platelet coverage compared to the
FIGURE 3. Representative images showing platelet adhesion and activation after incubation with PRP as visualized by immu-
nofluorescence staining for CD41 (in green, platelet marker) and CD62P (in red, activated platelet marker). (a) Bare silicon substrate
showing the FITC-labeled CD41 channel alone, (b) bare silicon substrate showing the Alexa 547-labeled CD62P channel alone,
(c) and (d) are corresponding images in bare polysilicon substrate. Scale bars represent 10 lm.
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unmodified single crystal silicon substrate (Figs. 4d–
4g). Platelet counts (both activated and non-activated)
are also significantly lower on these surfaces compared
to unmodified silicon as seen in Fig. 5 (p< 0.001).
This indicates that surface modification significantly
reduces platelet adhesion and activation on the silicon
surface. Of the four types of modifications that were
tested, pSBMA alone shows slightly higher levels of
platelet adhesion and activation as seen from the
platelet counts and the mean platelet size in Fig. 5.
However, platelet counts on the pSBMA substrate are
still 8-fold lower compared to that of unmodified sili-
con substrate.
Previously it has been shown that PEG modification
significantly reduces protein adsorption and throm-
bosis on silicon-based substrates.7,25 Moreover, PEG
films have been shown to retain their ability to reduce
protein fouling for up to four weeks under aqueous
in vivo-like conditions.29 Platelet adhesion on PVAm
coated polycarbonate disks has been shown to be
~90% less than that of uncoated disks.10 pSBMA
grafted surfaces have also been shown to reduce
platelet adhesion and activation.2 These results are in
good agreement with our data indicating that surface
modification can be used to significantly improve
the hemocompatibility of silicon for implant devices.
FIGURE 4. Superimposed images of the FITC-labeled CD41 (green) and Alexa 547-labeled CD62P (red) show colocalization of
platelet adhesion and activation as seen in yellow: (a) Bare silicon, (b) bare polysilicon, (c) ADP/silicon, (d) liquid PEG/silicon,
(e) vapor PEG/silicon, (f) PVAm/silicon, (g) pSBMA/silicon, and (h) Teflon. Scale bars represent 10 lm.
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Of considerable interest is the fact that platelet adhe-
sion and activation levels on the modified silicon sub-
strates (with the exception of pSBMA) are not
significantly different from that of Teflon (Fig. 4h).
This result is encouraging as it indicates that surface
modification reduces platelet activation on silicon to
levels comparable to that of Teflon, a material that is
extensively used in medical implant devices.
Pilot studies conducted in rats using silicon implants
with and without PEG conjugation have shown that
PEG-conjugated silicon implants showed no thrombus
formation compared to bare silicon implants which
had significant adherent thrombi.21 This data is in
excellent agreement with our studies showing that
surface modification using polymers such as PEG sig-
nificantly reduces platelet adhesion and activation on
silicon. While these results are very encouraging, these
preliminary studies need to be extended to examine
long-term blood compatibility of silicon membranes
under flow-based conditions that are relevant to the
end application of dialysis. Future work should also
focus on investigating different markers of hemocom-
patibility in vivo to evaluate the feasibility of silicon
membranes for use in implantable renal replacement
systems.
CONCLUSION
Any device that is brought into contact with blood
causes adverse reactions thus compromising the
hemocompatibility of the device. Such reactions are
particularly challenging in the case of hemodialyzers
which come into chronic contact with blood. It is
therefore very important to evaluate the blood com-
patibility of silicon surfaces before they can be used in
the development of implantable renal replacement
units. Our studies show that unmodified single crystal
silicon and polysilicon substrates display low levels of
coagulation and complement activation, comparable
to that of Teflon and stainless steel—two materials
extensively used in implant applications. Both these
surfaces also perform considerably better in these
aspects when compared to DEAE cellulose, a com-
mercially available material used in dialysis mem-
branes. The unmodified silicon substrates, however,
display significantly higher levels of platelet activation
compared to Teflon, although these values are still
substantially lower than that with ADP (~10-fold), a
known agonist of platelet activation.
Of considerable interest is the fact that silicon sub-
strates modified with PEG and PVAm polymers
showed excellent performance comparable to Teflon in
all four aspects of hemocompatibility—surface coagu-
lation, complement and platelet activation, and adhe-
sion, respectively. Thus, surface modification improves
the blood compatibility of silicon to levels comparable
to medical grade implant materials such as Teflon. All
the surface modifications that were tested (PEG,
PVAm, and pSBMA) were also far superior to DEAE
cellulose in terms of coagulation and complement
activation. This is encouraging as it suggests that sur-
face-modified silicon substrates have the potential to
perform significantly better than some of the currently
FIGURE 5. Platelet adhesion and activation after incubation of substrates with PRP: The vertical axis on the left represents the
number of activated and non-activated platelets attached to the substrate as visualized by immunofluorescence staining for CD41
(platelet marker) and CD62P (activated platelet marker). Data is presented as average 6 standard deviation of 12 images. *p< 0.001
vs. corresponding platelet counts in vapor PEG/silicon. The vertical axis on the right represents mean platelet size. Data is
presented as average 6 95% confidence interval of 12 images. #p< 0.001 vs. corresponding size in vapor PEG/silicon. Teflon could
not be used as reference because platelet count on Teflon was zero.
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available materials used in dialyzers. Collectively, our
results demonstrate that the surface-modified silicon
substrates may be used in the development of mem-
branes for implantable biomedical devices.
ELECTRONIC SUPPLEMENTARY MATERIAL
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